Published: 12 February 2024
Author(s): Karel J. van Erpecum, George N. Dalekos
Issue: May 2024
Section: Editorial

The collection 'New horizons in the diagnosis and management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD)’ that is presented here, deals with the natural history, non-invasive tests and risk stratification, associated cardiovascular risk, and treatment options and MASLD management including pharmacological treatment options for this disease. In recent years, steatotic liver disease (SLD) -previously known as fatty liver disease- has replaced viral hepatitis as the most common liver disease worldwide due to the spread of the Western diet and the increasing prevalence of obesity as well as the introduction of highly effective antiviral therapy.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.